GENEVA — The World Health Organization's vaccine experts have said countries may now consider routinely offering the human papillomavirus (HPV) vaccine to girls aged 4 to 8, a striking shift from the long-standing focus on pre-teens, as global coverage sits at just 33 percent — far below the 90 percent target set for eliminating cervical cancer as a public health problem.
Illustration: A young child receiving a vaccination at a health clinic, symbolizing the WHO experts' proposal to consider HPV vaccination from age 4.
What Happened
On 13 October 2026, the WHO's Strategic Advisory Group of Experts on Immunization (SAGE) presented its latest recommendations at a press briefing following its meeting of 5 to 8 October. The headline change concerns the age at which routine HPV vaccination may begin. SAGE chair Anthony Scott told reporters that around 165 countries have already introduced HPV vaccination programmes, but that global coverage remains stuck at about one in three girls.
"However, the global HPV vaccine coverage, at 33 percent, is far short of the global target we're looking for, which is 90 percent," Scott said, according to reporting of the briefing. SAGE's answer is flexibility: countries may consider routine vaccination of girls aged 4 to 8 with a single dose, if doing so is likely to increase uptake and coverage — for example, by reaching children through early-childhood health visits or school-entry programmes that already exist in many countries.
The recommendation does not replace the existing priority group. SAGE reaffirmed that vaccination of girls aged 9 to 14 remains the highest priority, and concluded, after reviewing updated evidence, that a single-dose schedule for that age group is now the most efficient approach to reaching the global target. The group also set out the order in which the single-dose strategy may be extended to other groups: first catch-up vaccination for women up to age 25, then up to age 30, followed by routine vaccination of boys aged 9 to 14, and finally catch-up vaccination for males up to age 20. People with weakened immune systems should continue to receive at least two doses, SAGE said.
The advice matters because cervical cancer remains one of the world's deadliest cancers for women. Persistent infection with high-risk HPV types causes cervical cancer, which ranked as the fifth most commonly diagnosed cancer among women worldwide in 2024, according to the WHO, with around 604,000 new cases and approximately 280,000 deaths that year. Kate O'Brien, director of the WHO's Department of Immunization, Vaccines and Biologicals, said more than 95 million girls had received HPV vaccines by the end of 2025 — real progress, but far from enough.
Background
HPV is one of the most common viral infections in the world, spread mainly through intimate skin-to-skin contact. Most infections clear on their own, but persistent infection with certain high-risk types can lead, over years, to cervical cancer and other cancers. Vaccination works best before exposure to the virus, which is why programmes have traditionally targeted girls just before adolescence.
In 2022, the WHO recommended a one- or two-dose schedule for girls aged 9 to 14, the same schedule for young women aged 15 to 20, and two doses six months apart for women over 21. The move to a single dose for the core age group was itself a major simplification, designed to stretch limited supplies and reach more girls with fewer clinic visits. The October 2026 update goes further, concluding on updated evidence that the single dose for ages 9 to 14 is the most efficient route to the 90 percent goal — and that starting even earlier, where it helps coverage, should be on the table.
The 90 percent target sits inside the WHO's global strategy to eliminate cervical cancer, which also calls for 70 percent of women to be screened and 90 percent of women with cervical disease to receive treatment. Vaccination is the first pillar, and the weakest: at 33 percent global coverage, two out of three girls worldwide are still missing out. The burden falls hardest on low- and middle-income countries, where screening and treatment are also hardest to access, and where most cervical cancer deaths occur.
SAGE's advice comes at a moment of tight health budgets worldwide. Health Policy Watch noted that the same October meeting produced a package of recommendations aimed at helping countries stretch vaccine supplies — including the single-dose HPV approach — as funding pressures grow. In that context, an option that lets countries vaccinate younger children during visits they already make, rather than building entirely new adolescent programmes, could be genuinely useful.
Illustration: A protective shield over a globe with vaccine vials, symbolizing how HPV vaccination prevents cervical cancer worldwide.
Why It Matters
The age-4 proposal matters for a simple reason: the girls being missed today are the cervical cancer cases of the 2040s and 2050s. Cervical cancer develops slowly, which means today's vaccination decisions cast a very long shadow. Every percentage point of coverage gained now translates into cancers prevented decades from now — and every year of delay leaves another cohort unprotected.
Starting younger could also solve a practical problem that has dogged HPV programmes for years. Adolescent vaccination is notoriously hard to deliver: teenagers visit clinics less often than young children, school-based programmes need consent systems and cold chains, and in many countries girls who have left school are the hardest to reach of all. Children aged 4 to 8, by contrast, are far more likely to be in contact with health services and primary schools. If a country can fold an HPV dose into an existing early-childhood visit, it may reach girls it would otherwise miss entirely.
There are also equity stakes. The 33 percent global average hides enormous gaps: some high-income countries have coverage above 80 percent, while many low-income countries are far below the average. A more flexible age window does not fix funding or supply problems on its own, but it gives health ministries another tool — and SAGE's careful wording, "if this is likely to result in increased vaccination uptake and coverage," makes clear that countries should adopt the younger age only where it genuinely helps.
Parents, meanwhile, should note what the recommendation is not. It is not a mandate to vaccinate four-year-olds everywhere, and it does not change the core advice: girls aged 9 to 14 remain the priority group, and a single dose is the recommended schedule for them. The 4-to-8 option is an additional route to the same goal, not a replacement for the existing programme.
What Happens Next
National health authorities will now decide whether, and how, to act on SAGE's advice. Countries with strong early-childhood health systems may move first, piloting the younger age window in districts where it promises the biggest coverage gains. Others may wait for WHO's full position paper and for guidance on consent, communication and programme costs. Vaccine manufacturers and donors will also be watching: any expansion of the eligible age range affects demand forecasts and supply planning.
Researchers will be tracking two questions closely. First, does vaccinating at ages 4 to 8 actually raise coverage, or does it simply shift the same doses earlier? Second, does protection last? The single-dose strategy rests on evidence that one dose provides strong protection; extending that logic to younger children will need follow-up studies on how long immunity endures into the years of highest risk. SAGE's own documents stress that immunocompromised people still need at least two doses — a reminder that one size does not fit all.
Advocates for cervical cancer elimination will press governments not to let the new flexibility become an excuse for inaction on the core programme. The fastest route to 90 percent remains the same: reach every girl aged 9 to 14 with a single dose, catch up young women who missed out, and extend vaccination to boys in sequence. The 4-to-8 option is best understood as a new door into that programme, not a different building.
For families, the practical message is unchanged but worth repeating: HPV vaccination is safe, effective, and most valuable before exposure to the virus. Parents unsure about timing should ask their local health service what their country's programme offers — and know that, wherever they live, the global goal is the same: a generation of girls who never have to face cervical cancer at all.
Illustration: Health experts at an international briefing, symbolizing the WHO advisory group that issued the new HPV guidance.
Sponsored: explore today's featured sponsored offers
FAQ
What did the WHO experts actually recommend about HPV vaccination age?
SAGE said countries may consider routine HPV vaccination of girls aged 4 to 8 with a single dose, if doing so is likely to increase uptake and coverage. Girls aged 9 to 14 remain the highest-priority group, with a single-dose schedule recommended as the most efficient approach.
Does this mean all four-year-olds should now get the HPV vaccine?
No. The recommendation is an option for countries, not a global mandate. Each country decides based on whether the younger age window would genuinely improve its coverage, and parents should follow their own national programme.
Why is global HPV coverage only 33 percent?
According to SAGE chair Anthony Scott, around 165 countries have introduced HPV programmes, but delivery — especially to adolescents — remains difficult, and funding pressures are growing. The 33 percent figure is far below the WHO's 90 percent target for cervical cancer elimination.
How serious is cervical cancer worldwide?
Very serious: the WHO reports around 604,000 new cases and approximately 280,000 deaths in 2024, making it the fifth most commonly diagnosed cancer among women globally. Most deaths occur in low- and middle-income countries.
Is one dose of the HPV vaccine enough?
SAGE concluded, after reviewing updated evidence, that a single-dose schedule for girls aged 9 to 14 is the most efficient approach to the global target. People with weakened immune systems should still receive at least two doses.
Sources
- World Health Organization, SAGE meeting highlights, 5–8 October 2026 — HPV vaccine recommendations, including the 4–8 years option and single-dose schedule for ages 9–14.
- MedicalXpress / AFP, "WHO experts recommend HPV shot for girls aged 4–8," 13 October 2026 — SAGE briefing, Scott quotes, 165 countries, 33 percent coverage, 604,000 cases and 280,000 deaths in 2024.
- Health Policy Watch, "Experts Recommend Ways To Stretch Vaccine Supplies In Face Of Dwindling Budgets," October 2026 — SAGE package, single-dose strategy and expansion order.
- News Central TV, "WHO Recommends HPV Vaccine for Girls Aged 4–8," 13 October 2026 — briefing details and 2022 schedule background.
Comments
Post a Comment